Angle-supported intraocular-lens implantation for the correction of moderate to high myopia
Kevin Matthew Serafin B. Panggat, MD, Jesus Francisco, III, MD, Pik Sha Chan, MD, Harvey Uy, MD
This study evaluated the efficacy and safety of an angle-supported phakic intraocular lens (PIOL) for the treatment of moderate to high myopia.
This is a case series of 13 eyes of 8 patients with moderate to high myopia that underwent implantation of an acrylic, angle-supported PIOL. The main outcome measures were manifest refraction, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), endothelial-cell count (ECC), intraocular pressure (IOP), and adverse events.
The mean spherical equivalent (SE) improved from –11.79 ± 4.12 diopters (D) preoperatively to –0.08 ± 0.58 D postoperatively (p = 0.000), UCVA from 0.016 ± 0.015 to 0.79 ± 0.29 postoperatively (p = 0.000), and BCVA from 0.76 ± 0.33 to 0.86 ± 0.27 (p = 0.017). The ECC slightly decreased from 3033.57 ± 367.71 cells/mm2 preoperatively to 2947 ± 279.86 cells/mm2 (2.8% loss) postoperatively (p = 0.400). The mean preoperative IOP was 16.36 ± 3.53 mm Hg while the mean three-month postoperative IOP was 15.72 ± 4.15 mm Hg (p = 0.659). Two (15%) eyes experienced transient postoperative IOP rise on the day of the surgery, which resolved by postoperative day 1 using topical timolol maleate. The mean follow-up was 2.54 ± 1.39 months (range, 1 to 5 months).
Acrylic angle-supported phakic intraocular lens (PIOL) implantation is an effective and safe method of correcting moderate to high myopia.
Keywords:Angle-supported phakic intraocular lens, Refractive surgery, Endothelialcell count, High myopia